International Journal of Medical and Pharmaceutical Case Reports

Introduction: Aplastic anemia is a rare but serious hematological disorder characterized by bone marrow failure leading to pancytopenia. The condition often presents with nonspecific symptoms, resulting in delayed diagnosis and an increased risk of life-threatening complications. Early identification and appropriate management are crucial for improving patient outcomes.

Case Presentation: A 23-year-old female with a known history of aplastic anemia presented with heavy menstrual bleeding and generalized weakness. Laboratory investigations revealed severe pancytopenia, including markedly reduced hemoglobin, leukocyte, and platelet counts. Bone marrow findings were consistent with a hypocellular marrow. The patient was treated with supportive measures such as packed red blood cell and platelet transfusions, along with immunosuppressive therapy using cyclosporine and adjunctive agents, including danazol and tranexamic acid.

Discussion: Aplastic anemia is primarily an immune-mediated disorder characterized by the destruction of hematopoietic stem cells. Accurate differentiation from other causes of pancytopenia is essential for effective management. Immunosuppressive therapy remains the mainstay of treatment for patients who are not eligible for hematopoietic stem cell transplantation, with regular monitoring required to evaluate response and prevent complications.

Conclusion: This case emphasizes the challenges in diagnosing and managing aplastic anemia in young adults. Early recognition and timely supportive care with immunosuppressive therapy are crucial for improving clinical outcomes, survival, and quality of life.